CRYSTAL ENGINEERING OF ANTIVIRAL AGENT EFAVIRENZ FOR SOLUBILITY ENHANCEMENT by Gadade, Dipak D et al.
Gadade et al                                                                                                           Journal of Drug Delivery & Therapeutics. 2018; 8(1):86-91                    
ISSN: 2250-1177                                                                               [86]                                                                              CODEN (USA): JDDTAO 
Available online on 15.01.2018 at http://jddtonline.info 
Journal of Drug Delivery and Therapeutics 
Open Access to Pharmaceutical and Medical Research 
© 2011-18, publisher and licensee JDDT, This is an Open Access article which permits unrestricted 
non-commercial use, provided the original work is properly cited 
Open  Access                                                                                                                     Research Article 
CRYSTAL ENGINEERING OF ANTIVIRAL AGENT EFAVIRENZ FOR 
SOLUBILITY ENHANCEMENT 
Gadade Dipak D.*
1
, Pekamwar Sanjay S.
1
., Shirsat Mahendra D
.2
 
1
 School of Pharmacy, S.R.T.M. University, Vishnupuri, Nanded (India) - 431606 
2
 RUSA Centre for Advanced Sensor Technology University Campus, Aurangabad (India) – 431004  
 
ABSTRACT 
In the current study, we attempted to improve the physicochemical properties of antiviral drug efavirenz through the cocrystal 
synthesis. The neat grinding performed to study the effect of coformer-fumaric acid (FA) on solubility and dissolution of efavirenz, 
which can serve as the green cocrystal synthesis approach. The prepared cocrystals were characterized for characteristics like 
powder flow properties, aqueous saturation solubility, in vitro powder dissolution study. The synthesized cocrystals were 
characterized by Fourier transform infrared spectroscopy, differential scanning calorimetry, powder X-ray diffraction. The formation 
of a cocrystal of efavirenz and caffeine was confirmed by the characterization techniques which suggests the interactions between 
efavirenz and coformer-fumaric acid leads to cocrystal formation. The powder flow properties, solubility, and dissolution profile of 
efavirenz are significantly improved by its cocrystallization.  
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1. INTRODUCTION 
Crystal engineering or solid state supramolecular 
synthesis deals with the understanding of intermolecular 
interactions in the context of crystal packing and in 
applying this understanding to the design of pre-desired 
crystal structures with specific physical or chemical 
properties
1.’ Co-crystals are solids that are crystalline 
materials composed of two or more molecules in the 
same crystal lattice. Given the association of two or 
more molecules in the co-crystal lattice, it is useful to 
consider the association of components more generally 
2
. 
Neat grinding method without utilizing any solvents
 3,4
 
or by solvent drop grinding
5
, where the small or 
acceptable amount of solvent is utilized which 
ultimately evaporate during synthetic process
 6,7
 can be 
used to cocrystals green synthesis method. It is outcome 
of non-covalent interactions which include hydrogen 
bonding, dipole interactions, π-π interactions, ion-π 
interactions, halogen bonding, closed shell interactions 
or van der Waals interactions. The selection of the 
second component in cocrystal synthesis i.e. coformer is 
crucial in the development of multicomponent systems. 
The properties of coformers decide the fate of cocrystal 
system; it has implications on physicochemical 
properties as well as the pharmacokinetic behaviour of 
cocrystals 
8
.  
Efavirenz, (4S)-6-chloro-4- (cyclopropylethynyl)-4-
(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazine-2-
one, is a HIV-1 specific, non-nucleoside reverse 
transcriptase inhibitor
9
. It was approved for the 
treatment of human immunodeficiency virus type-1 
infection (HIV-1). Efavirenz (EFV) belongs to 
Biopharmaceutical Classification System (BCS) class II. 
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Being poorly water soluble drug, significant differences 
in bioavailability can be observed in the various 
polymorphic forms of EFV 
10
. Previous studies reported 
attempts to improve solubility and dissolution of EFV 
by solid dispersion and drug milling 
11,12
. It was also 
revealed that EFV shows improved pharmaceutical 
properties by cocrystallization with adipic acid 
13
, lactic 
acid 
14
,  glutaric acid 
15
. 
In this work we attempted to prepare cocrystals of EFV 
with fumaric acid (FA) for enhancement of 
pharmaceutically physicochemical properties of EFV, 
and to characterize the cocrystals using powder Fourier 
transform infrared (FTIR), differential scanning 
calorimetry (DSC), powder X-ray powder diffraction 
(PXRD), saturation solubility and dissolutions. 
2. MATERIAL AND METHODS 
EFV was obtained as gift sample from Mylan 
Laboratories, Hyderabad. FA was procured from 
Research Fine Lab, Mumbai. All other chemicals and 
solvents employed in present work were of analytical 
grade and procured from Research Fine Lab, Mumbai. 
2.1 Miscibility of the components 
Hansen solubility parameters of EFV and FA were 
computed by using the group contribution method 
following the collective utilization models of Fedors and 
Van Krevelen–Hoftyzer. The solubility parameter 
components were computed from group contributions 
(F) and molar volume (Vm), using the following 
equations where δd represent dispersion forces energy, 
δp represents polar forces energy and δh represents 
hydrogen bonding energy 
16,17
. 
δd = (∑Fdi/∑Vm)  (1) 
δp =([∑Fpi]0.5/∑Vm)   (2)  
δh = (∑Fhi /∑Vm)0.5  (3) 
δt = (δ2 d + δ2p + δ2h)0.5  (4) 
Miscibility of components can be predicted according to 
predictive principle that if Δδt < 7 MPa0.5 of the 
components they may be miscible and forms 
multicomponent system and hence, if this criterion is 
fulfilled the cocrystal may be formed. 
2.2 Preparation of cocrystals 
Cocrystals of EFV with coformers were prepared by the 
neat grinding method. A stoichiometric mixture of EFV 
and coformer-FA (1:1 M) was ground in an agate mortar 
with a pestle for about 20 mins by neat grinding method 
(NG). The obtained cocrystals were used for 
characterization 
18
.  
2.3 Micromeritic properties 
The active pharmaceutical ingredient-EFV and its 
corystals with FA was evaluated for various 
micromeritic flow properties that is bulk density, tapped 
density, Carr’s index, Hausner’s ratio and angle of 
repose 
19
. 
2.4 ATR-Fourier transform infrared spectroscopy 
(FTIR) 
Fourier transform infrared spectroscopy (FTIR) was 
employed for the vibrational spectroscopic analysis of 
the active pharmaceutical ingredient (API)-EFV and its 
cocrystals with a coformer-FA obtained by NG method 
18
. The FTIR spectrums were recorded with the FTIR 
spectrophotometer with ATR attachment (Bruker; 
ALPHA-T) and the scanning range was in between 
4000-660 cm
-1
.   
2.5 Thermal Analysis 
Differential scanning calorimetry (DSC) studies were 
performed using Shimadzu TA-60WS Module to 
understand the thermal characteristics of an EFV alone 
and its cocrystal with FA. Weighed samples were heated 
in aluminum pans at a rate of 20ºC/min, from 50 to 
300ºC temperature range, under a nitrogen atmosphere 
and empty aluminum pan  were used as a reference
20,21
. 
2.6 Powder X-ray diffraction (PXRD) 
PXRD patterns were obtained using a Bruker D8 
Advance X-ray diffractometer (Cu Kα radiation). A 
continuous scanning method was used for recording 
with a fixed tube current (32 mA) and a 40 kV voltage. 
The scanning range of 5-50° (2θ) was used to measure 
the diffraction intensities of powder samples of API and 
cocrystals 
22
.  
2.7 Saturation Solubility Study  
Solubility studies EFV and its cocrystal with FA was 
performed in accordance method reported by Higuchi 
and Connors 
23
. For saturation solubility, an excess 
quantity of cocrystal powder was added to distilled 
water. The vials were then subjected to rotary shaking 
for 24 hours and filtrate obtained after filtration through 
the 0.2µm pore size membrane filter (Whatman
®
) was 
analyzed by UV spectrophotometer at 247.6 nm. 
2.8 Powder Dissolution Study and Intrinsic 
dissolution rate study (IDR) 
Powder dissolution study of EFV and its cocrystal with 
FA was performed using 2% aqueous sodilum lauryl 
sulphate as dissolution medium at 37±0.5ºC. An aliquot 
of dissolution medium was withdrawn at 10, 15, 30, 45, 
and 60 min intervals and concentration of API was 
determined at 247.6 nm spectro-photometrically. 
The intrinsic dissolution rate of EFV and EFV-FA 
cocrystals was evaluated to study dissolution of API per 
unit area and time. The tablets of EFV and EFV-FA 
cocrystals with hardness 8 kg/cm
2
 were compressed. 
The tablet compacts were coated using paraffin wax, 
leaving only the surface under investigation free for 
dissolution and affixed to the paddle of USP dissolution 
apparatus. The IDR studies were performed in 2%SLS 
at 37°C for 120 mins. The intrinsic dissolution rate 
(IDR) was determined from the slope of the dissolution 
time profiles
24
. 
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3. RESULTS AND DISCUSSION 
3.1 Miscibility of the components 
Solubility parameters (δt) for EFV and FA were 
computed using the group contribution method 
following the collective utilization models of Fedors and 
Van Krevelen–Hoftyzer and reported in the table 1.  
Table 1: Solubility parameters (HSP) for EFV and FA 
Particulars  δd* δp* δh* δt* 
EFV 28.56 7.16 7.55 30.40 
FA 17.38  7.07  15.43  24.29  
*(MJ/m
3
)
1/2 
The resulting ∆δ value for EFV and FA is 6.11 
(MJ/m
3
)
1/2
 which indicates the miscibility of an API 
with the coformer-FA
16)
 as ∆δ value <7. It indicates that 
the components are miscible consequently may result in 
formation of cocrystal 
19,25
.
 
3.2 Micromeritic properties 
Carr’s index and Hausner’s ratio were derived from bulk 
density and tapped density of materials (Table 2). Carr’s 
Index and Hausner’s ratio for unprocessed EFV were 
fits into passable scale while these properties for EFV-
FA cocrystal can be scaled into good to fair flow 
property on the scale of flowability
26
. It shows improved 
flow properties of later against unprocessed EFV.
Table 1: Micromeritic properties of EFV and its cocrystal 
Material Bulk Density (g/cm
3
) Tapped density(g/cm
3
) Carr’s Index Hausner Ratio Angle of repose 
EFV* 0.2535±0.0015 0.3288±0.0045 22.89±1.15% 1.30±0.019 43.99º± 2.39º 
Cocrystal* 0.3521± 0.0049 0.4145±0.0104 17.93±0.99% 1.17±0.013 36.94º±1.66º 
*(n=3) 
3.3 Vibrational spectroscopic study 
The assignments to the major vibrational peaks in the 
FTIR spectral studies 
27
 (Fig.1) were as elucidated in 
table 3. The additional new peaks were observed in 
spectrum of EFV-FA cocrystal at 1681.48 cm
-1 
and 
3742.82 cm
-1 
which can assigned to aliphatic alkene and 
hydroxyl functions in the fumaric acid respectively. The 
peak of tri-fluoro-alkane function in the EFV was 
shifted from 1325.00 cm
-1 
to 1317.52 cm
-1 
suggesting its 
participation in intermolecular interactions. These peaks 
may be assigned to halogen bonding interaction between 
fluorine functions of EFV with cyclic amine function of 
FA due to cocrystal formation. The additional peaks 
observed are marked in sprectrum which suggests the 
formation cocrystal. 
Table 2: Assignment of vibrational frequencies to 
EFV and its cocrystal 
EFV (cm
-1
) EFV FA Cocrystal (cm
-1
) 
Group FTIR Group FTIR 
NH 3311.97, 
806.95 
NH 3312.23, 
807.32 
CH 1495.28 CH3 3087.72 
Alkyne 2247.52 Alkyne 2247.62 
C=O 1745.67 C=O 1746.49 
-Ar-C=C 1601.35 -Ar-C=C 
C=C 
1601.82 
1681.48 
-CF3 1325.00 -CF3 1317.52 
-C-O-C 1188.50 -C-O-C 1188.15 
-C-Cl 1074.87 -C-Cl 1074.33 
-OH -- -OH 3742.82 
 
 
Figure 1 FTIR spectra of EFV and EFV-FA cocrystal 
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3.4 Thermal Analysis 
EFV shows melting at 140.15 ºC with heat 48.61 J/g 
which was confirmed to be its form I from reported 
literature 
9,10.
 EFV-FA cocrystal shows melting at 208.76 
ºC and an additional peak at 266.76ºC were observed in 
DSC thermogram (Fig. 2). It indicates formation of new 
phase which altered melting behaviour and which 
supports to assumption of EFV-FA cocrystal formation. 
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Figure 2 DSC thermogram of EFV and EFV-FA cocrystal 
 
3.5 Powder X-ray diffraction (PXRD) 
PXRD study was employed to assess transformations in 
the crystallographic nature of an API and coformer 
subsequent to the cocrystallization (Fig. 3). In 
correlation with the reported data
28
 for EFV, a very 
intense peak was observed around 2Ɵ of 6.26 along with 
10.80, 11.26, 12.1, 13.6, 14.54, 15.56, 17.1, 19.18, 20.3, 
21.4 and 25.04.  In contrast to PXRD pattern of EFV, 
additional characteristic distinct multiple sharp peaks 
were observed at 2Ɵ of 28.79, 29.41, 38.62 in the 
diffractogram of cocrystal which can be assigned to the 
formation of new crystalline phases in cocrystal of EFV-
FA 
29
.  
 
 
Figure 3 PXRD diffractograms of EFV, FA and their cocrystal 
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3.6 Saturation Solubility Study 
Saturated solubility of EFV was found to be 8.39 
(±0.10) µg/ml in distilled water and it was improved in 
cocrystal form with FA to 223.6 (±11.88)µg/ml. It 
clearly indicates solubility advantage of cocrystal 
formation of EFV-FA. It demonstrates that solubility of 
cocrystal form is as result of molecular transformation 
by non-covalent interaction in the crystalline material. 
3.7 Powder Dissolution Study 
Powder dissolution study of API-EFV and Cocrystal of 
EFV with FA shows a clear improvement of cocrystal 
formation.  
 
4. CONCLUSIONS 
Cocrystals of EFV-FA were obtained by neat grinding 
approach of green synthesis. The new cocrystal of EFV 
with FA shows improved pharmaceutical characteristics 
particularly, micromeritic flow properties, solubility and 
dissolution against unprocessed EFV. The prepared 
cocrystals were confirmed by FTIR spectroscopy, DSC 
and PXRD. The vibrational spectroscopy-FTIR, 
revealed the possible halogen bonding interactions 
between EFV and EFV-FA cocrystals could be 
formulated in an immediate release dosage form to 
attain a rapid and complete release of the API available 
for absorption overcoming problem of low solubility of 
drug which can be explored to industrial scale.  
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Figure 4 a) Powder dissolution study in 2% SLS b) intrinsic dissolution study of EFV and EFV-FA cocrystals 
 
Only 34.52 (±1.22%) EFV was released from API 
powder in comparison with 75.70 (±0.66%) from 
cocrystal powder at the end of 60 min in powder 
dissolution study (Fig.4a). The obvious improvement in 
dissolution characteristics of cocrystal can be correlated 
to intermolecular interactions between EFV and FA. 
The IDR of EFV was 126.38±18.51µg/min/cm
2 
while 
that EFV-FA cocrystal was 148.78±10.58 µg/min/cm
2 
as 
determined from the slope of dissolution curve (Fig. 4b). 
EFV dissolved more rapidly from the cocrystal tablet 
formulation that API tablets, consistent with the 
solubility studies outcomes. 
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